{"success":true,"data":{"pressRelease":{"id":"153377","rtpr_id":"nGNX808NYq-20260925","ticker":"BIOA","exchange":"NASDAQ","all_tickers":["BIOA"],"title":"BioAge Labs to Present at Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-09-25T20:30:00.147Z","article_body":"EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(NASDAQ: BIOA) (\"BioAge\", \"the Company\"), a clinical-stage biotechnology\ncompany developing therapeutic product candidates for cardiometabolic diseases\nby targeting the biology of human aging, today announced that the Company will\nparticipate in the following upcoming investor conferences:\n\n• ROTH Healthcare Opportunities Conference (New York, September 29, 2026):\nBJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate\nDirector, Strategy & Investor Relations, will participate in one-on-one\nmeetings.\n\n• Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan,\nPhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on\nWednesday, September 30 at 1 PM EDT. BJ Sullivan, Dov Goldstein, MD, CFO, and\nAlexis Jakubowski, Associate Director, Strategy & Investor Relations, will\nparticipate in one-on-one meetings. To access the live webcast of the\npresentation, register here\n(https://www.globenewswire.com/Tracker?data=KkaobtvAaNEZ__F3RKLp1BMJXR7WnhraVj-5LGueBgqEpnY-OFY5_jGccigFF69pjbeEpNA83LSfP2SRhMUdwyklFDNOyLSus6vHSlcQRJ0c4etcyU20esm8yNnR6yHNClmN3ixnWKO2Re8J5hcfpPq1IGDlYJAWM7bq79Xhsr69dw1JO8L3TU8NLLkEYzgq09GeWyZmHmimQxGvLu6TAVFDMqIYghi0m1GJpOda9EXSPMl8-sHNKY-R_jcDEoyOCyMX9OpWjOhH0hHKPpv35wTxR0PvWGpFudbJXu9SSbb-K7_YMk_jFdE8p3GNb4kglJ8qFkGttDAb6QJ0z_r7ULpXT7EOmiit_wTJ8cH0aoWWetgthVTebmaUiyOa9ZRMvI1g-NS33a5ckv4fZvrzj7Y5-sl9ffuseEV9dlhiboE=).\n\nReplays of the presentations will be available in the investor section of the\nCompany's website at https://ir.bioagelabs.com/, and will be archived for 30\ndays following the presentations.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company's lead product candidate, BGE-102, is a potent,\norally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for diseases driven by inflammation, including diabetic macular\nedema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial\ndemonstrating a well-tolerated profile and potential best-in-class reductions\nin hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular\nproof-of-concept data from QUELL-CV are anticipated in the second half of\n2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated\nin the second half of 2027. The Company is also developing long-acting\ninjectable and oral small molecule APJ agonists for obesity. BioAgeʼs\nadditional preclinical programs, which leverage insights from the Companyʼs\nproprietary discovery platform built on human longevity data, address key\npathways involved in metabolic aging.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX808NYq-20260925","title":"BioAge Labs to Present at Upcoming Investor Conferences","author":"Globe Newswire","ticker":"BIOA","created":"2026-09-25T20:30:00.147Z","tickers":["BIOA"],"exchange":"NASDAQ","article_body":"EMERYVILLE, Calif., Sept. 25, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc.\n(NASDAQ: BIOA) (\"BioAge\", \"the Company\"), a clinical-stage biotechnology\ncompany developing therapeutic product candidates for cardiometabolic diseases\nby targeting the biology of human aging, today announced that the Company will\nparticipate in the following upcoming investor conferences:\n\n• ROTH Healthcare Opportunities Conference (New York, September 29, 2026):\nBJ Sullivan, Dov Goldstein, MD, CFO, and Alexis Jakubowski, Associate\nDirector, Strategy & Investor Relations, will participate in one-on-one\nmeetings.\n\n• Stifel Virtual Cardiometabolic Forum (September 30, 2026): BJ Sullivan,\nPhD, Chief Strategy Officer, is scheduled to participate in a fireside chat on\nWednesday, September 30 at 1 PM EDT. BJ Sullivan, Dov Goldstein, MD, CFO, and\nAlexis Jakubowski, Associate Director, Strategy & Investor Relations, will\nparticipate in one-on-one meetings. To access the live webcast of the\npresentation, register here\n(https://www.globenewswire.com/Tracker?data=KkaobtvAaNEZ__F3RKLp1BMJXR7WnhraVj-5LGueBgqEpnY-OFY5_jGccigFF69pjbeEpNA83LSfP2SRhMUdwyklFDNOyLSus6vHSlcQRJ0c4etcyU20esm8yNnR6yHNClmN3ixnWKO2Re8J5hcfpPq1IGDlYJAWM7bq79Xhsr69dw1JO8L3TU8NLLkEYzgq09GeWyZmHmimQxGvLu6TAVFDMqIYghi0m1GJpOda9EXSPMl8-sHNKY-R_jcDEoyOCyMX9OpWjOhH0hHKPpv35wTxR0PvWGpFudbJXu9SSbb-K7_YMk_jFdE8p3GNb4kglJ8qFkGttDAb6QJ0z_r7ULpXT7EOmiit_wTJ8cH0aoWWetgthVTebmaUiyOa9ZRMvI1g-NS33a5ckv4fZvrzj7Y5-sl9ffuseEV9dlhiboE=).\n\nReplays of the presentations will be available in the investor section of the\nCompany's website at https://ir.bioagelabs.com/, and will be archived for 30\ndays following the presentations.\n\nAbout BioAge Labs, Inc.\n\nBioAge is a clinical-stage biopharmaceutical company developing therapeutic\nproduct candidates for cardiometabolic diseases by targeting the biology of\nhuman aging. The Company's lead product candidate, BGE-102, is a potent,\norally bioavailable, brain-penetrant small-molecule NLRP3 inhibitor being\ndeveloped for diseases driven by inflammation, including diabetic macular\nedema and cardiovascular risk. BGE-102 has completed a Phase 1 SAD/MAD trial\ndemonstrating a well-tolerated profile and potential best-in-class reductions\nin hsCRP and other inflammatory biomarkers. Phase 2 cardiovascular\nproof-of-concept data from QUELL-CV are anticipated in the second half of\n2026, and Phase 2 diabetic macular edema data from QUELL-DME are anticipated\nin the second half of 2027. The Company is also developing long-acting\ninjectable and oral small molecule APJ agonists for obesity. BioAgeʼs\nadditional preclinical programs, which leverage insights from the Companyʼs\nproprietary discovery platform built on human longevity data, address key\npathways involved in metabolic aging.\n\nContacts\nPR: Chris Patil, media@bioagelabs.com \nIR: Dov Goldstein, ir@bioagelabs.com \nPartnering: partnering@bioagelabs.com \nWeb: https://bioagelabs.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d6df9eb5-87f7-4e2e-b503-8a7d8651428e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-25T20:30:00.179269894Z","server_sent_at_ms":1790368200179},"received_at":"2026-09-25T20:30:00.288Z","source_url":null},"analysis":{"id":"142178","press_release_id":"153377","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"BioAge Labs will participate in the ROTH Healthcare Opportunities Conference on September 29 and the Stifel Virtual Cardiometabolic Forum on September 30, 2026.\n\nExecutives including CSO BJ Sullivan, CFO Dov Goldstein, and IR lead Alexis Jakubowski will hold one-on-one meetings, with a Stifel fireside chat webcast on September 30 at 1 PM EDT.\n\nThe release reiterates pipeline timing: Phase 2 QUELL-CV cardiovascular proof-of-concept data for BGE-102 expected in the second half of 2026 and QUELL-DME diabetic macular edema data in the second half of 2027.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference participation notice — no new data; investors may still want the webcast link ahead of H2 2026 QUELL-CV readout."},"keyFigures":{},"namedEntities":{"people":[{"name":"BJ Sullivan","role":"Chief Strategy Officer"},{"name":"Dov Goldstein, MD","role":"CFO"},{"name":"Alexis Jakubowski","role":"Associate Director, Strategy & Investor Relations"},{"name":"Chris Patil","role":"PR contact"}],"products":["BGE-102","QUELL-CV","QUELL-DME"],"companies":[{"name":"BioAge Labs, Inc.","ticker":"BIOA"},{"name":"Roth","relationship":"conference host"},{"name":"Stifel","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference participation announcement with no new clinical, financial, or strategic disclosure. Boilerplate corporate communications."},"tickerRelevance":{"others":[],"primary":"BIOA"},"globalImportance":8,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap-clinical-stage","eventGravity":"routine-investor-conference","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"BioAge Labs will participate in the ROTH Healthcare Opportunities Conference on September 29 and the Stifel Virtual Cardiometabolic Forum on September 30, 2026.\n\nExecutives including CSO BJ Sullivan, CFO Dov Goldstein, and IR lead Alexis Jakubowski will hold one-on-one meetings, with a Stifel fireside chat webcast on September 30 at 1 PM EDT.\n\nThe release reiterates pipeline timing: Phase 2 QUELL-CV cardiovascular proof-of-concept data for BGE-102 expected in the second half of 2026 and QUELL-DME diabetic macular edema data in the second half of 2027.","key_figures":{},"named_entities":{"people":[{"name":"BJ Sullivan","role":"Chief Strategy Officer"},{"name":"Dov Goldstein, MD","role":"CFO"},{"name":"Alexis Jakubowski","role":"Associate Director, Strategy & Investor Relations"},{"name":"Chris Patil","role":"PR contact"}],"products":["BGE-102","QUELL-CV","QUELL-DME"],"companies":[{"name":"BioAge Labs, Inc.","ticker":"BIOA"},{"name":"Roth","relationship":"conference host"},{"name":"Stifel","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-25T20:30:04.761Z","global_importance":8,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap-clinical-stage","eventGravity":"routine-investor-conference","issuerAuthored":true}},"durationMs":4455,"modelName":"glm-5.3-flashx"}}